On-demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden:: differences in treatment characteristics and outcome

被引:93
作者
Carlsson, KS
Höjgård, S
Glomstein, A
Lethagen, S
Schulman, S
Tengborn, L
Lindgren, A
Berntorp, E
Lindgren, B
机构
[1] Lund Univ, Ctr Hlth Econ, SE-22007 Lund, Sweden
[2] Malmo Univ Hosp, Dept Community Med, Lund, Sweden
[3] Inst Hemophilia, Oslo, Norway
[4] Lund Univ, Dept Coagulat Disorders, Malmo Univ Hosp, Malmo, Sweden
[5] Karolinska Hosp, Dept Med, Div Haematol, S-10401 Stockholm, Sweden
[6] Sahlgrens Univ Hosp, Dept Internal Med Cardiol & Vasc Surg, S-41345 Gothenburg, Sweden
[7] Lund Inst Technol, Ctr Math Sci, Lund, Sweden
关键词
days lost from work; factor-concentrate consumption; haemophilia-related surgery; longitudinal data; treatment characteristics; treatment strategy;
D O I
10.1046/j.1365-2516.2003.00817.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Using an 11-year panel of 156 Norwegian and Swedish patients with severe haemophilia, and including retrospective case-book data from birth, we compared the differences in the haemophilia-related resource use between on-demand and prophylactic treatment. Patients treated on-demand had more surgery (arthrodeses, prostheses implantations and synovectomies) and more days lost from work. Median annual factor-concentrate consumption among adults (18+) was 211 000 IU [interquartile range (IQR) 154 000-268 000] or 3 024 IU kg(-1) year(-1) for patients on prophylactic treatment and 55 000 IU (IQR 28 000-91 000) for on-demand patients (780 IU kg(-1) year(-1)). This was partly explained by the fact that the median dose per kg body weight was twice as great 28, (IQR 24-32) prophylaxis compared with 14 (IQR 12-16) for on-demand. Prescribed dose per kg body weight was found to be an important factor explaining the variation in total annual factor-concentrate consumption per patient for both types of treatment. Other variables included in the panel-data regression analysis were the number of weeks on secondary prophylaxis for on-demand patients and age, body weight and type of haemophilia for children (0-17 years) on prophylaxis. Differences were consistently substantial and will affect both costs and benefits of the two treatment strategies.
引用
收藏
页码:555 / 566
页数:12
相关论文
共 35 条
[31]  
Schramm W, 2002, HAEMOPHILIA, V8, P33, DOI 10.1046/j.1365-2516.2002.00580.x
[32]  
Siegel S., NONPARAMETRIC STAT B
[33]   Socioeconomic impact of haemophilia care: Results of a pilot study [J].
Szucs, TD ;
Offner, A ;
Schramm, W .
HAEMOPHILIA, 1996, 2 (04) :211-217
[34]   MORTALITY IN PATIENTS WITH HEMOPHILIA - CHANGES IN A DUTCH POPULATION FROM 1986 TO 1992 AND 1973 TO 1986 [J].
TRIEMSTRA, M ;
ROSENDAAL, FR ;
SMIT, C ;
VANDERPLOEG, HM ;
BRIET, E .
ANNALS OF INTERNAL MEDICINE, 1995, 123 (11) :823-+
[35]   Long-term outcome of individualized prophylactic treatment of children with severe haemophilia [J].
van den Berg, HM ;
Fischer, K ;
Mauser-Bunschoten, EP ;
Beek, FJA ;
Roosendaal, G ;
van der Bom, JG .
BRITISH JOURNAL OF HAEMATOLOGY, 2001, 112 (03) :561-565